UROGEN DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds UroGen Pharma (URGN) Investors of the July 28th Deadline and Urges Investors to Inquire About Their Rights in Class Action Lawsuit
Class Action Lawsuit Against UroGen Pharma: A class action lawsuit has been filed against UroGen Pharma for allegedly making misleading statements regarding its drug UGN-102, which is intended to treat bladder cancer. Investors who purchased shares between July 27, 2023, and May 15, 2025, are encouraged to contact Bragar Eagel & Squire, P.C. for legal options.
Impact of FDA Findings on Stock Price: Following negative findings from the FDA regarding the clinical study design of UGN-102, UroGen's stock price dropped significantly, falling nearly 26% after the FDA's briefing document was released and an additional 45% after the Oncologic Drugs Advisory Committee voted against the drug's approval.
Trade with 70% Backtested Accuracy
Analyst Views on URGN
About URGN
About the author
Wildcat Capital Exits UroGen Pharma Position, Liquidating Approximately $6.79 Million
- Complete Exit: Wildcat Capital Management disclosed in an SEC filing on November 13 that it sold all 495,606 shares of UroGen Pharma, liquidating approximately $6.79 million, which reduces its investment stake from 4% to 0%.
- Stock Performance: UroGen Pharma's shares have surged 113% over the past year, currently priced at $23.52, significantly outperforming the overall market, which has only risen 15%, indicating strong performance in the biotech sector.
- Investment Background: Founded in 2011 as the single-family office of billionaire investor David Bonderman, Wildcat has historically favored concentrated investments over short-term trading, making this exit appear more like disciplined capital recycling rather than a lack of confidence in the company.
- Future Outlook: While UroGen's Jelmyto remains its commercial anchor and the pipeline targets significant unmet needs in urothelial cancers, the volatility in biotech stocks suggests that this exit may signal that investors believe the best returns have already been realized.
Significant Options Trading on Wednesday: UTHR, URGN, DSGN
UroGen Pharma Options Activity: UroGen Pharma Ltd (URGN) has seen a significant options volume of 20,539 contracts today, equating to about 2.1 million underlying shares, which is 192% of its average daily trading volume over the past month.
High Volume Call Option for URGN: The $24 strike call option expiring on February 20, 2026, has particularly high activity with 10,010 contracts traded, representing approximately 1.0 million underlying shares.
Design Therapeutics Options Activity: Design Therapeutics Inc (DSGN) has recorded an options volume of 5,000 contracts today, representing around 500,000 underlying shares, which is 164.8% of its average daily trading volume over the past month.
High Volume Call Option for DSGN: The $9 strike call option expiring on January 16, 2026, has seen all 5,000 contracts traded today, corresponding to approximately 500,000 underlying shares.
D. Boral Capital Continues to Recommend Buying UroGen Pharma (URGN)
Analyst Recommendation: D. Boral Capital has maintained a Buy recommendation for UroGen Pharma, with a projected one-year price target of $34.42/share, indicating a potential upside of 97.96% from its current price of $17.39/share.
Fund Sentiment and Ownership Changes: There has been a 6.91% increase in the number of funds reporting positions in UroGen Pharma, with notable increases in ownership from firms like Rtw Investments and Jefferies Financial Group, while total shares owned by institutions decreased by 4.24% over the last three months.
Summit Takes Neutral Stance on Risk/Reward Dynamics as Piper Launches Coverage on Biotech Cancer Stocks
Piper Sandler's Coverage Launch: Piper Sandler initiated coverage on several cancer-focused biotech companies, giving a Neutral rating to Summit Therapeutics (SMMT) due to perceived high investor expectations and downside risks.
Revolution Medicines Rating: Revolution Medicines (RVMD) received an Overweight rating with a target price of $75 per share, driven by positive data for its lead asset daraxonrasib in treating pancreatic ductal adenocarcinoma.
Tango Therapeutics Potential: Analyst Kelsey Goodwin expressed optimism about Tango Therapeutics (TNGX), assigning an Overweight rating and a target of $11 per share, citing potential for its PRMT5-inhibitor TNG462 in various cancers.
UroGen Pharma Outlook: UroGen Pharma (URGN) was also rated Overweight with a target of $36 per share, as confidence grows around the market launch of its bladder cancer drug Zusduri and upcoming clinical updates.
HC Wainwright & Co. Maintains Buy on UroGen Pharma, Lowers Price Target to $40
Fastest News Alerts: Benzinga Pro offers real-time intelligence and news alerts to help traders stay informed and make winning trades in the stock market.
Exclusive Community Access: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.
D. Boral Capital Maintains Buy on UroGen Pharma, Maintains $25 Price Target
Fastest News Alerts: Benzinga Pro offers real-time intelligence and news alerts to help traders stay informed and make winning trades in the stock market.
Exclusive Community Access: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.
Wildcat Capital Exits UroGen Pharma Position, Liquidating Approximately $6.79 Million
- Complete Exit: Wildcat Capital Management disclosed in an SEC filing on November 13 that it sold all 495,606 shares of UroGen Pharma, liquidating approximately $6.79 million, which reduces its investment stake from 4% to 0%.
- Stock Performance: UroGen Pharma's shares have surged 113% over the past year, currently priced at $23.52, significantly outperforming the overall market, which has only risen 15%, indicating strong performance in the biotech sector.
- Investment Background: Founded in 2011 as the single-family office of billionaire investor David Bonderman, Wildcat has historically favored concentrated investments over short-term trading, making this exit appear more like disciplined capital recycling rather than a lack of confidence in the company.
- Future Outlook: While UroGen's Jelmyto remains its commercial anchor and the pipeline targets significant unmet needs in urothelial cancers, the volatility in biotech stocks suggests that this exit may signal that investors believe the best returns have already been realized.
Significant Options Trading on Wednesday: UTHR, URGN, DSGN
UroGen Pharma Options Activity: UroGen Pharma Ltd (URGN) has seen a significant options volume of 20,539 contracts today, equating to about 2.1 million underlying shares, which is 192% of its average daily trading volume over the past month.
High Volume Call Option for URGN: The $24 strike call option expiring on February 20, 2026, has particularly high activity with 10,010 contracts traded, representing approximately 1.0 million underlying shares.
Design Therapeutics Options Activity: Design Therapeutics Inc (DSGN) has recorded an options volume of 5,000 contracts today, representing around 500,000 underlying shares, which is 164.8% of its average daily trading volume over the past month.
High Volume Call Option for DSGN: The $9 strike call option expiring on January 16, 2026, has seen all 5,000 contracts traded today, corresponding to approximately 500,000 underlying shares.
D. Boral Capital Continues to Recommend Buying UroGen Pharma (URGN)
Analyst Recommendation: D. Boral Capital has maintained a Buy recommendation for UroGen Pharma, with a projected one-year price target of $34.42/share, indicating a potential upside of 97.96% from its current price of $17.39/share.
Fund Sentiment and Ownership Changes: There has been a 6.91% increase in the number of funds reporting positions in UroGen Pharma, with notable increases in ownership from firms like Rtw Investments and Jefferies Financial Group, while total shares owned by institutions decreased by 4.24% over the last three months.
Summit Takes Neutral Stance on Risk/Reward Dynamics as Piper Launches Coverage on Biotech Cancer Stocks
Piper Sandler's Coverage Launch: Piper Sandler initiated coverage on several cancer-focused biotech companies, giving a Neutral rating to Summit Therapeutics (SMMT) due to perceived high investor expectations and downside risks.
Revolution Medicines Rating: Revolution Medicines (RVMD) received an Overweight rating with a target price of $75 per share, driven by positive data for its lead asset daraxonrasib in treating pancreatic ductal adenocarcinoma.
Tango Therapeutics Potential: Analyst Kelsey Goodwin expressed optimism about Tango Therapeutics (TNGX), assigning an Overweight rating and a target of $11 per share, citing potential for its PRMT5-inhibitor TNG462 in various cancers.
UroGen Pharma Outlook: UroGen Pharma (URGN) was also rated Overweight with a target of $36 per share, as confidence grows around the market launch of its bladder cancer drug Zusduri and upcoming clinical updates.
HC Wainwright & Co. Maintains Buy on UroGen Pharma, Lowers Price Target to $40
Fastest News Alerts: Benzinga Pro offers real-time intelligence and news alerts to help traders stay informed and make winning trades in the stock market.
Exclusive Community Access: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.
D. Boral Capital Maintains Buy on UroGen Pharma, Maintains $25 Price Target
Fastest News Alerts: Benzinga Pro offers real-time intelligence and news alerts to help traders stay informed and make winning trades in the stock market.
Exclusive Community Access: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.
